Allulose and GLP-1: A Close Read of the Actual Research (2026)
Share
By Brandon, founder of Ozzi · Published August 16, 2026 · Updated October 31, 2026
If you want the beginner version, start with the allulose supplement guide or our post on whether allulose spikes blood sugar.
What did the human GLP-1 trials actually measure?
One 2022 human trial in 18 healthy normal-weight adults found that CCK, GLP-1 and PYY all rose significantly versus water after 25g of D-allulose was delivered directly into the stomach through a tube.
Three caveats matter, and most write-ups skip all three.
First, n = 18. That's a mechanistic study, not a population finding.
Second, the dose was 25g, given intragastrically. That is roughly triple what most people would put in a drink, and it bypassed the mouth entirely.
Third, the published abstract reports "GLP-1" without specifying active versus total. Total GLP-1 includes the fragment your body has already broken down with DPP-4. Active GLP-1 is the part still capable of hitting the receptor. We can't tell from the abstract which one moved here.
Which studies say what? The evidence table
The allulose trials that found the impressive GLP-1 mechanism ran in rats and mice. Read the species column before you read the result column.
| Study | Species / population | n | Dose | What was measured | Result |
|---|---|---|---|---|---|
| Teysseire 2022, J Nutr | Human, healthy, normal weight | 18 | 25g, intragastric, single dose | GLP-1, CCK, PYY (active vs total not specified); gastric emptying | All three hormones rose vs water, P < 0.0001. Blocking sweet taste receptors changed nothing. Allulose did not slow gastric emptying |
| Sitticharoon 2023, Eur J Nutr | Human, type 2 diabetes, under medical care | 16 | 7g twice daily (14g/day) for 12 weeks | Incretin levels, glucose homeostasis, body composition, lipids | No significant change in incretins, glucose control or body composition. HDL-C fell from 51 to 41 mg/dL, MCP-1 rose |
| Osborn 2026, Am J Clin Nutr (meta-analysis) | Human, pooled across 20 trials | 1,033 total (12 allulose trials) | Varied | Postprandial glucose and insulin, HbA1c, lipids, body composition. GLP-1 was not pooled | Postprandial glucose down (SMD -0.66) and insulin down (SMD -1.27), both moderate certainty. No effect on HbA1c, fasting glucose, lipids or body fat |
| Hira 2025, Endocrinology | Rat, male | Not stated in abstract | Luminal, varied volumes | GLP-1 secretion vs intestinal content volume and diameter | GLP-1 tracked the absolute amount of allulose, independent of concentration, and correlated with physical intestinal distension |
The proposed pathway, with the evidence tier marked at each step. The gold steps are the ones that have only been shown in animals or cells.
Why did the sweet taste receptor theory fall apart?
In the human trial, researchers co-administered lactisole at 450 ppm, a sweet taste receptor antagonist. If the receptor were the route, blocking it should flatten the hormone response. It didn't. All three hormones still rose, and lactisole had no measurable effect (all P > 0.1). The authors state it plainly: the response "is not mediated via T1R2/T1R3 in the gut."
In rats, the same test was run with different tools and got the same answer. A 2018 study found allulose-induced GLP-1 secretion was abolished by xanthohumol, a glucose and fructose transport inhibitor, but was not blocked by an SGLT1 inhibitor or by a sweet taste receptor inhibitor.
So what mechanism does the animal work actually support?
The animal work on allulose and GLP-1 supports three candidate mechanisms, all preclinical and all in rodents: transport-mediated sensing, physical distension and a vagus nerve relay.
None has a human counterpart. When you see "allulose talks to your brain through the vagus nerve" in marketing copy, that sentence is describing rodent neuroscience.
What has the research actually studied in clinical populations?
This section covers trials run in people with diagnosed metabolic conditions. Those participants were patients under medical supervision, enrolled in registered clinical trials. Nothing here describes what a supplement does for a healthy person, and none of it is a reason to change how you manage a diagnosed condition. Talk to your doctor about that.
The most important of these is a 2023 double-blind randomized crossover trial in 16 patients with type 2 diabetes at Siriraj Hospital in Bangkok.
The result: no significant effect on glucose homeostasis, incretin levels, or body composition. Two secondary findings went the wrong way. HDL cholesterol dropped from 51 mg/dL to 41 mg/dL (P < 0.001) and MCP-1, an inflammatory marker, rose from 259 to 297 pg/mL (P = 0.002).
That is the only chronic human trial that looked at incretins, and it was null. It's also small, it was registered retrospectively, and the lipid finding hasn't been replicated.
The broadest human picture comes from a 2026 systematic review and meta-analysis in the American Journal of Clinical Nutrition, covering 20 controlled trials and 1,033 participants, 12 of them allulose trials.
The pooled human evidence supports a real acute glycemic effect and does not currently support a body composition effect.
Does an acute GLP-1 rise mean anything for appetite?
For allulose in humans, an acute GLP-1 rise has not been shown to mean anything for appetite: in the one human trial that measured both hormones and appetite ratings, allulose moved the hormones without moving the subjective appetite measures.
If you want the wider view on raising GLP-1 without a prescription, we cover the whole category in how to increase GLP-1 naturally and compare ingredients head to head in allulose vs berberine.
How does 8g compare to the doses in the studies?
Ozzi's Crave Crusher uses 8g of allulose per stick. Being straight about where that sits:
- The human trial that found a GLP-1 rise used 25g, delivered by tube. Ozzi is well under that.
- The human glucose trials that found dose-dependent effects used 2.5g to 7.5g alongside a carbohydrate load. Ozzi is at or slightly above that range.
- The 12-week diabetes trial that found nothing on incretins used 14g a day, split into two doses.
So: 8g is a real dose that overlaps the low end of the human glycemic literature. It is not a replication of the trial that measured GLP-1, and we're not going to pretend it is. Allulose is well tolerated at moderate intakes and less so at large ones, which we cover in allulose side effects and is allulose safe.
If you want the full ingredient walkthrough, the GLP-1 booster drink guide covers it.
Where does the evidence get thin, and who funded it?
The evidence gets thin at the human GLP-1 base, which is one positive trial with 18 people, and the industry affiliations are author affiliations with two allulose producers, Matsutani Chemical Industry and Samyang Corp., rather than formal funding statements.
One trial we can't cite yet. A German trial called LisA was designed with postprandial GLP-1 as its primary outcome. 10 participants completed it, sample collection finished in November 2023, and analysis was expected around mid-2026. Only the protocol has been published.
For the bigger picture on what GLP-1 does and why anyone cares, start with our pillar on what GLP-1 is.
Frequently asked questions
Has allulose been proven to raise GLP-1 in humans?
One randomized controlled trial in 18 healthy adults found a significant rise after 25g given intragastrically. A separate 12-week trial in 16 people with type 2 diabetes found no change in incretins at 14g a day. Two human trials, one positive, one null.
Does allulose slow gastric emptying?
In the one human trial that measured it, no. Erythritol slowed gastric emptying in that trial (P = 0.0002). Allulose did not.

Made with 8g of allulose
Ozzi Crave Crusher
One watermelon stick a day: 8g allSWEET allulose, 500mg konjac glucomannan, 500mg BIOMEnd L-lysine butyrate, 300mcg chromium, 10mg ursolic acid and 150mg African mango. No caffeine and no stimulants.
See what's in it →References
- Teysseire F, et al. The Role of D-allulose and Erythritol on the Activity of the Gut Sweet Taste Receptor and Gastrointestinal Satiation Hormone Release in Humans: A Randomized, Controlled Trial. J Nutr. 2022;152(5):1228-1238. doi:10.1093/jn/nxac026 (human, n=18)
- Sitticharoon C, et al. Short-term effects of allulose consumption on glucose homeostasis, metabolic parameters, incretin levels, and inflammatory markers in patients with type 2 diabetes: a double-blind, randomized, controlled crossover clinical trial. Eur J Nutr. 2023;62(7):2939-2948. doi:10.1007/s00394-023-03205-w (human, n=16, type 2 diabetes)
- Osborn L, et al. Glycemic and cardiometabolic effects of rare sugars allulose and tagatose: a systematic review and meta-analysis of controlled human intervention trials. Am J Clin Nutr. 2026;123(6):101314. doi:10.1016/j.ajcnut.2026.101314 (human, 20 trials, 1,033 participants)
- Iida T, et al. Acute D-psicose administration decreases the glycemic responses to an oral maltodextrin tolerance test in normal adults. J Nutr Sci Vitaminol. 2008;54(6):511-4. doi:10.3177/jnsv.54.511 (human, n=20)
- Hayashi N, et al. Study on the postprandial blood glucose suppression effect of D-psicose in borderline diabetes and the safety of long-term ingestion by normal human subjects. Biosci Biotechnol Biochem. 2010;74(3):510-9. doi:10.1271/bbb.90707 (human, n=26 and n=17)
- Kimura T, et al. d-Allulose enhances postprandial fat oxidation in healthy humans. Nutrition. 2017;43-44:16-20. doi:10.1016/j.nut.2017.06.007 (human, n=13)
- Hayakawa M, et al. Secretion of GLP-1 but not GIP is potently stimulated by luminal d-Allulose (d-Psicose) in rats. Biochem Biophys Res Commun. 2018;496(3):898-903. doi:10.1016/j.bbrc.2018.01.128 (rat)
- Iwasaki Y, et al. GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nat Commun. 2018;9(1):113. doi:10.1038/s41467-017-02488-y (mouse and rat)
- Hira T, et al. Intestinal Distension Induced by Luminal D-allulose Promotes GLP-1 Secretion in Male Rats. Endocrinology. 2025;166(2). doi:10.1210/endocr/bqaf002 (rat)
- Kohno D, et al. D-Allulose cooperates with glucagon-like peptide-1 and activates proopiomelanocortin neurons in the arcuate nucleus and central injection inhibits feeding in mice. Biochem Biophys Res Commun. 2022;613:159-165. doi:10.1016/j.bbrc.2022.04.027 (mouse, ex vivo neurons)
- Park SY, et al. D-Allulose Regulates Obesity via Endoplasmic Reticulum Stress-Mediated Glucagon-Like Peptide-1 Receptor Pathway. Antioxid Redox Signal. 2025;43(16-18):819-832. doi:10.1177/15230864251399183 (mouse and cell culture; two authors affiliated with Samyang Corp.)
- Iwasaki Y, et al. Gut-Derived GLP-1 Released by Rare Sugar d-Allulose Cooperates With Insulin to Activate Left-Sided Vagal Afferents and Enhance Insulin Sensitivity. Diabetes. 2026;75(7):1086-1100. doi:10.2337/db25-1134 (mouse)
- Storcksdieck genannt Bonsmann S, et al. Effects of Allulose vs Aspartame Consumption on Postprandial Glucagon-Like Peptide-1 Profiles and Metabolic Health: Protocol for a Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. JMIR Res Protoc. 2026;15:e81857. doi:10.2196/81857 (human protocol only, no results published)
Study records retrieved from PubMed. Every citation above was checked for retraction status before inclusion.
About the author
I'm Brandon, the founder of Ozzi. I built this company because I got tired of supplement brands citing rodent studies as if they were human ones. I read the papers myself, I check the sample sizes, and when the evidence is thin I say so on our own product pages. If a claim can't survive a look at the methods section, it doesn't belong in our copy.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is educational and is not medical advice. Talk to your healthcare provider before starting any supplement, especially if you manage a diagnosed condition or take prescription medication.
